keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer

keyword
https://www.readbyqxmd.com/read/29161775/the-influence-of-different-peptide-combinations-to-increase-the-immunogenicity-of-the-gonadotrophin-releasing-hormone-vaccine-for-prostate-cancer-treatment
#1
Franklin Fuentes Aguilar, Jesús Junco Barranco, Lesvia Calzada Aguilera, Eddy Bover Fuentes, Jose André Serradelo Leal, Eduardo Hernández López, Eulogio Pimentel Vázquez, Roberto Basulto Baker, Osvaldo Reyes Acosta, Hilda Garay Pérez, Gerardo Guillén Nieto
Purpose: Therapeutic vaccines, specifically the Gonadotrophin Releasing Hormone (GnRH) vaccine, are considered an additional therapeutic option for advanced stage prostate cancer. Our work showed amplification of the immune response when combining two peptides with and without the Very Small Size Proteoliposomes (VSSP). VSSP is a potent adjuvant for dendritic cells activation and Th1 differentiation. as enhanced immune response. Methods: The test was carried out in Copenhagen rats as animal model...
November 2017: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/29161715/management-of-biochemical-recurrence-after-primary-curative-treatment-for-prostate-cancer-a-review
#2
Walter Artibani, Antonio Benito Porcaro, Vincenzo De Marco, Maria A Cerruto, Salvatore Siracusano
How to manage patients with prostate cancer (PCa) with biochemical recurrence (BCR) following primary curative treatment is a controversial issue. Importantly, this prostate-specific antigen (PSA)-only recurrence is a surrogate neither of PCa-specific survival nor of overall survival. Physicians are therefore challenged with preventing or delaying the onset of clinical progression in those deemed at risk, while avoiding over-treating patients whose disease may never progress beyond PSA-only recurrence. Adjuvant therapy for radical prostatectomy (RP) or local radiotherapy (RT) has a role in certain at-risk patients, although it is not recommended in low-risk PCa owing to the significant side-effects associated with RT and androgen deprivation therapy (ADT)...
November 21, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/29161520/ezh2-histone-methyltransferase-and-jmjd3-histone-demethylase-implications-in-prostate-cancer
#3
Mouhamed Idrissou, Marine Daures, Amani Ben Jemia, Gaëlle Judes, Khaldoun Rifaï, Frédérique Penault-Llorca, Yves-Jean Bignon, Laurent Guy, Dominique Bernard-Gallon
No abstract text is available yet for this article.
November 21, 2017: Omics: a Journal of Integrative Biology
https://www.readbyqxmd.com/read/29161337/age-at-diagnosis-and-prostate-cancer-treatment-and-prognosis-a-population-based-cohort-study
#4
A Pettersson, D Robinson, H Garmo, L Holmberg, P Stattin
Background: Old age at prostate cancer diagnosis has been associated with poor prognosis in several studies. We aimed to investigate the association between age at diagnosis and prognosis, and if it is independent of tumor characteristics, primary treatment, year of diagnosis, mode of detection and comorbidity. Patients and methods: We conducted a nation-wide cohort study including 121,392 Swedish men aged 55-95 years in Prostate Cancer data Base Sweden (PCBaSe) 3...
November 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29161239/the-impact-of-folate-intake-on-the-risk-of-head-and-neck-cancer-in-the-prostate-lung-colorectal-and-ovarian-cancer-screening-trial-plco-cohort
#5
Daisuke Kawakita, Yuan-Chin Amy Lee, Lisa H Gren, Saundra S Buys, Carlo La Vecchia, Mia Hashibe
BACKGROUND: Although low levels of folate leads to disturbances in DNA replication, DNA methylation and DNA repair, the association between dietary folate intake and head and neck cancer (HNC) risk remains unclear. METHODS: We evaluated the association between folate intake and HNC risk using prospective cohort data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. This study included 101 700 participants and 186 cases with confirmed incident HNC...
November 21, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29160866/prostate-cancer-a-nervous-disposition-the-angiometabolic-switch
#6
Louise Stone
No abstract text is available yet for this article.
November 21, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29160846/a-triphenylphosphonium-functionalized-mitochondriotropic-nanocarrier-for-efficient-co-delivery-of-doxorubicin-and-chloroquine-and-enhanced-antineoplastic-activity
#7
Katerina N Panagiotaki, Zili Sideratou, Spiros A Vlahopoulos, Maria Paravatou-Petsotas, Michael Zachariadis, Nikolas Khoury, Vassilis Zoumpourlis, Dimitris Tsiourvas
Drug delivery systems that target subcellular organelles and, in particular, mitochondria are considered to have great potential in treating disorders that are associated with mitochondrial dysfunction, including cancer or neurodegenerative diseases. To this end, a novel hyperbranched mitochondriotropic nanocarrier was developed for the efficient co-delivery of two different (both in chemical and pharmacological terms) bioactive compounds. The carrier is based on hyperbranched poly(ethyleneimine) functionalized with triphenylphosphonium groups that forms ~100 nm diameter nanoparticles in aqueous media and can encapsulate doxorubicin (DOX), a well-known anti-cancer drug, and chloroquine (CQ), a known chemosensitizer with arising potential in anticancer medication...
November 21, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/29160310/cyclin-d-cdk4-kinase-destabilizes-pd-l1-via-cul3-spop-to-control-cancer-immune-surveillance
#8
Jinfang Zhang, Xia Bu, Haizhen Wang, Yasheng Zhu, Yan Geng, Naoe Taira Nihira, Yuyong Tan, Yanpeng Ci, Fei Wu, Xiangpeng Dai, Jianping Guo, Yu-Han Huang, Caoqi Fan, Shancheng Ren, Yinghao Sun, Gordon J Freeman, Piotr Sicinski, Wenyi Wei
Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit(1,2). However, many cancer patients fail to respond to anti-PD-1/PD-L1 treatment, and the underlying mechanism(s) is not well understood(3-5). Recent studies revealed that response to PD-1/PD-L1 blockade might correlate with PD-L1 expression levels in tumor cells(6,7). Hence, it is important to mechanistically understand the pathways controlling PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1/PD-L1 blockade in cancer patients...
November 16, 2017: Nature
https://www.readbyqxmd.com/read/29159872/the-dark-side-of-glucose-transporters-in-prostate-cancer-are-they-a-new-feature-to-characterize-carcinomas
#9
REVIEW
Pedro Gonzalez-Menendez, David Hevia, Juan C Mayo, Rosa M Sainz
One of the hallmarks of cancer cells is the increased ability to acquire nutrients, particularly glucose and glutamine. Proliferating cells need precursors for cell growth and NADPH reducing equivalents for survival. The principal responsible for glucose uptake is facilitative glucose transporters (GLUTs), which usually are overexpressed in cancer cells. Besides their role in glucose uptake, GLUT transporters are able to transport other compounds such as dehydroascorbic acid or uric acid. They play a major role in tumor progression and cellular processes such as regulated cell death...
November 21, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29159379/in-localized-prostate-cancer-radical-prostatectomy-and-observation-did-not-differ-for-mortality-at-13-years
#10
Kari A O Tikkinen, Gordon H Guyatt
No abstract text is available yet for this article.
November 21, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/29159180/the-influence-of-serum-prostate-specific-antigen-on-the-accuracy-of-magnetic-resonance-imaging-targeted-biopsy-versus-saturation-biopsy-in-patients-with-previous-negative-biopsy
#11
Chao-Hsiang Chang, Hung-Chieh Chiu, Wei-Ching Lin, Tzu-Lung Ho, Han Chang, Yi-Huei Chang, Chi-Ping Huang, Hsi-Chin Wu, Chi-Rei Yang, Po-Fan Hsieh
Objective: We compared the prostate cancer (PCa) detection rates of targeted biopsy (TB) and saturation biopsy (SB) in patients with previous negative biopsy and the accuracy of TB and SB stratified by different serum prostate-specific antigen (PSA) levels. Materials and Methods: Overall 185 patients were enrolled. In the magnetic resonance imaging (MRI) group, 65 men underwent TB and SB. In the control group, 120 men underwent SB alone. The primary outcome was the difference in PCa detection rate between the MRI group and control group...
2017: BioMed Research International
https://www.readbyqxmd.com/read/29158832/clinical-translation-and-first-in-human-use-of-44-sc-sc-psma-617-for-pet-imaging-of-metastasized-castrate-resistant-prostate-cancer
#12
Elisabeth Eppard, Ana de la Fuente, Martina Benešová, Ambreen Khawar, Ralph A Bundschuh, Florian C Gärtner, Barbara Kreppel, Klaus Kopka, Markus Essler, Frank Rösch
BACKGROUND: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications...
2017: Theranostics
https://www.readbyqxmd.com/read/29158826/label-free-biochips-for-accurate-detection-of-prostate-cancer-in-the-clinic-dual-biomarkers-and-circulating-tumor-cells
#13
Lung-Hsuan Pan, See-Tong Pang, Po-Yu Fang, Cheng-Keng Chuang, Hung-Wei Yang
Purpose: Early diagnosis of prostate cancer (PCa) is essential for the prevention of metastasis and for early treatment; therefore, we aimed to develop a simple, accurate, and multi-analyte assay system for early PCa diagnosis in this study. Experimental design: We fabricated three kinds of biochips then integrated into microfluidic device for simultaneous detection of vascularendothelial growth factor (VEGF), prostate-specific antigen (PSA), and PCa circulating tumor cells (CTC) in human serum for accurate diagnosis of PCa...
2017: Theranostics
https://www.readbyqxmd.com/read/29158823/engineered-zn-ii-dipicolylamine-gold-nanorod-provides-effective-prostate-cancer-treatment-by-combining-sirna-delivery-and-photothermal-therapy
#14
Kyung Hyun Min, Young-Hwa Kim, Zhantong Wang, Jihoon Kim, Jee Seon Kim, Sun Hwa Kim, Kwangmeyung Kim, Ick Chan Kwon, Dale O Kiesewetter, Xiaoyuan Chen
Combination cancer treatment has emerged as a critical approach to achieve remarkable anticancer effect. In this study, we prepared a theranostic nanoformulation that allows for photoacoustic imaging as well as combination gene and photothermal therapy. Gold nanorods (GNR) were coated with dipicolyl amine (DPA), which forms stable complexes with Zn(2+) cations. The resulting nanoparticles, Zn(II)/DPA-GNR, recognize phosphate-containing molecules, including siRNA, because of the specific interaction between Zn(II) and the phosphates...
2017: Theranostics
https://www.readbyqxmd.com/read/29158807/the-prognostic-value-of-peripheral-benzodiazepine-receptor-in-patients-with-esophageal-squamous-cell-carcinoma
#15
You-Fang Chen, Jing-Dun Xie, Yu-Chuan Jiang, Dong-Tai Chen, Jia-Hao Pan, Yong-Hua Chen, Yun-Fei Yuan, Zhe-Sheng Wen, Wei-An Zeng
Background: The peripheral benzodiazepine receptor (PBR) has previously been reported as an oncogene in prostate, breast and colorectal cancers, but its prognostic value, biological behavior and function in esophageal squamous cell carcinoma (ESCC) has not been investigated. Methods: qRT-PCR, western blotting and immunohistochemistry (IHC) were used to detect PBR expression in ESCC and matched non-cancerous tissues. Based on all of the significantly independent factors, a nomogram was established to predict the prognosis of ESCC patients...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29158798/improvement-in-prediction-of-prostate-cancer-prognosis-with-somatic-mutational-signatures
#16
Shengping Zhang, Yafei Xu, Xinjie Hui, Fei Yang, Yueming Hu, Jianlin Shao, Hui Liang, Yejun Wang
Prostate cancer is a leading male malignancy worldwide, while the prognosis prediction remains quite inaccurate. The study aimed to observe whether there was an association between the prognosis of prostate cancer and genetic mutation profile, and to build an accurate prognostic predictor based on the genetic signatures. The patients diagnosed of prostate cancer from The Cancer Genomic Atlas were used for prognostic stratification, while the somatic gene mutation profiles were compared between different prognostic groups...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29158792/association-between-8q24-gene-polymorphisms-and-the-risk-of-prostate-cancer-a-systematic-review-and-meta-analysis
#17
Ran Li, Zhiqiang Qin, Jingyuan Tang, Peng Han, Qianwei Xing, Feng Wang, Shuhui Si, Xiaolu Wu, Min Tang, Wei Wang, Wei Zhang
Though numerous studies have been conducted to investigate the associations between five 8q24 polymorphisms (rs6983267 T>G, rs1447295 C>A, rs16901979 C>A, rs6983561 A>C and rs10090154 C>T) and prostate cancer (PCa) risk, the available results remained contradictory. Therefore, we performed a comprehensive meta-analysis to derive a precise estimation of such associations. We searched electronic databases PubMed, EMBASE, Web of Science and Wan Fang for the relevant available studies up to February 1st, 2017, and 39 articles were ultimately adopted in this meta-analysis...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29158516/prostate-shapes-on-pre-treatment-mri-between-prostate-cancer-patients-who-do-and-do-not-undergo-biochemical-recurrence-are-different-preliminary-findings
#18
Soumya Ghose, Rakesh Shiradkar, Mirabela Rusu, Jhimli Mitra, Rajat Thawani, Michael Feldman, Amar C Gupta, Andrei S Purysko, Lee Ponsky, Anant Madabhushi
Early identification of PCa patients at risk for biochemical recurrence (BCR) post-therapy will potentially complement definitive therapy with either neo- or adjuvant therapy to improve prognosis. BCR post definitive therapy is often associated with disease progression that might cause a bulge in the prostate gland. In this work we explored if an atlas-based comparison approach reveals shape differences in the prostate capsule as observed on pre-treatment T2-weighted MRI between prostate cancer patients who do (BCR (+)) and do not (BCR (-)) have BCR following definitive therapy...
November 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29158509/clinical-utility-of-the-prostate-health-index-phi-for-biopsy-decision-management-in-a-large-group-urology-practice-setting
#19
Jay White, B Vittal Shenoy, Ronald F Tutrone, Lawrence I Karsh, Daniel R Saltzstein, William J Harmon, Dennis L Broyles, Tamra E Roddy, Lori R Lofaro, Carly J Paoli, Dwight Denham, Mark A Reynolds
BACKGROUND: Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in the 4-10 ng/ml range can be challenging, because two-thirds of such biopsies are typically found to be benign. The Prostate Health Index (phi) exhibits significantly improved diagnostic accuracy for prostate cancer detection when compared to tPSA and %fPSA, however only one published study to date has investigated its impact on biopsy decisions in clinical practice. METHODS: An IRB approved observational study was conducted at four large urology group practices using a physician reported two-part questionnaire...
November 20, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29158269/the-glucocorticoid-receptor-is-a-key-player-for-prostate-cancer-cell-survival-and-a-target-for-improved-anti-androgen-therapy
#20
Martin Puhr, Julia Hoefer, Andrea Eigentler, Christian Ploner, Florian Handle, Georg Schaefer, Jan Kroon, Angela Leo, Isabel M Heidegger, Iris E Eder, Zoran Culig, Gabri van der Pluijm, Helmut Klocker
PURPOSE: The major obstacle in the management of advanced prostate cancer (PCa) is the occurrence of resistance to endocrine-therapy. Although the androgen receptor (AR) has been linked to therapy failure, the underlying escape mechanisms have not been fully clarified. Being closely related to the AR, the glucocorticoid receptor (GR) has been suggested to play a role in enzalutamide and docetaxel resistance. Given that glucocorticoids are frequently applied to PCa patients, it is essential to unravel the exact role of the GR in PCa progression...
November 20, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
113725
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"